Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
Source
169 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
RAISING FULL-YEAR GUIDANCE ACROSS ALL KEY METRICS
Cirrus Logic Reports Fiscal Second Quarter Revenue of $559.5 Million
PURSUIT REPORTS RECORD THIRD QUARTER 2026 RESULTS AND REAFFIRMS FULL YEAR ADJUSTED EBITDA GUIDANCE MIDPOINT
Sequentially, net sales increased 5.7%, gross profit increased 28.3% and
•Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2…
Compass Diversified Reports Third Quarter 2026 Financial Results
Record third quarter revenue of $190.2 million grew 20% year-over-year
Contribution ex-TAC(1) Grows 20% Year-Over-Year
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
Exceeded guidance with 11% Gross Bookings and 12% revenue growth y/y
Host Hotels & Resorts, Inc. Reports Results for the Third Quarter of 2026